IGM Biosciences Past Earnings Performance
Past criteria checks 0/6
IGM Biosciences's earnings have been declining at an average annual rate of -29.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 74.3% per year.
Key information
-29.6%
Earnings growth rate
16.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 74.3% |
| Return on equity | -278.5% |
| Net Margin | -7,534.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How IGM Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -220 | 51 | 0 |
| 30 Jun 24 | 3 | -220 | 45 | 0 |
| 31 Mar 24 | 2 | -237 | 48 | 0 |
| 31 Dec 23 | 2 | -246 | 50 | 0 |
| 30 Sep 23 | 2 | -238 | 50 | 0 |
| 30 Jun 23 | 2 | -234 | 50 | 0 |
| 31 Mar 23 | 2 | -229 | 50 | 0 |
| 31 Dec 22 | 1 | -221 | 50 | 0 |
| 30 Sep 22 | 1 | -219 | 50 | 0 |
| 30 Jun 22 | 0 | -205 | 47 | 0 |
| 31 Mar 22 | 0 | -185 | 43 | -24 |
| 31 Dec 21 | 0 | -165 | 38 | 0 |
| 30 Sep 21 | 0 | -139 | 32 | 20 |
| 30 Jun 21 | 0 | -115 | 27 | 35 |
| 31 Mar 21 | 0 | -95 | 22 | 74 |
| 31 Dec 20 | 0 | -81 | 18 | 0 |
| 30 Sep 20 | 0 | -72 | 16 | 58 |
| 30 Jun 20 | 0 | -61 | 14 | 51 |
| 31 Mar 20 | 0 | -53 | 12 | 44 |
| 31 Dec 19 | 0 | -43 | 9 | 35 |
| 30 Sep 19 | 0 | -37 | 7 | 30 |
| 30 Jun 19 | 0 | -34 | 6 | 27 |
| 31 Mar 19 | 0 | -27 | 5 | 22 |
| 31 Dec 18 | 0 | -23 | 4 | 19 |
Quality Earnings: 1K0 is currently unprofitable.
Growing Profit Margin: 1K0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1K0 is unprofitable, and losses have increased over the past 5 years at a rate of 29.6% per year.
Accelerating Growth: Unable to compare 1K0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1K0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 1K0 has a negative Return on Equity (-278.47%), as it is currently unprofitable.